Publicaciones

  • Quetglas J.I., Fioravanti J., Ardaiz N., Medina-Echeverz J., Baraibar I., Prieto, J. Smerdou C.*, Berraondo P.* (2012) A Semliki Forest virus vector engineered to express IFN induces efficient elimination of established tumors. Gene Therapy. 19(3):271-8.
    ABSTRACT CORTESÍA DE PUBMED

  • Quetglas J.I., Dubrot J., Bezunartea J., Sanmamed M.F., Hervas-Stubbs S., Smerdou C.*, Melero I.* (2012) Immunotherapeutic synergy between anti-CD137 mAb and intratumoral admistration of a cytopathic Semliki Forest virus encoding IL-12. Molecular Therapy. 20(9):1664-1675.
    ABSTRACT CORTESÍA DE PUBMED

  • Quetglas J.I., John L.B., Kershaw M.H., Alvarez-Vallina L., Melero I., Darcy P.K, Smerdou C. (2012) Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. OncoImmunology. 1:8, 1344-1354.
    ABSTRACT CORTESÍA DE PUBMED

  • Ansorena E., Casales E., Aranda A., Tamayo E., Garbayo E., Smerdou C.*, Blanco-Prieto M.J., Aymerich M.S.* (2013) A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system. International Journal of Pharmaceutics. 440:19-26.
    ABSTRACT CORTESÍA DE PUBMED

  • Quetglas J.I., Rodriguez-Madoz J.R., Bezunartea J., Ruiz-Guillen M., Casales E., Medina-Echeverz J., Prieto J., Berraondo P., Hervas-Stubbs S., Smerdou C. (2013). Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses. J. Immunology. 190:2994-3004.
    ABSTRACT CORTESÍA DE PUBMED

  • Quetglas J.I., Hervas-Stubbs S., Smerdou C. (2013). Immunological profiles of tumor-bearing animals determine the outcome of cancer immunotherapy. OncoImmunology. Jun 1;2(6):e24499. Epub 2013 Apr 16.
    ABSTRACT CORTESÍA DE PUBMED

  • Rodriguez-Madoz J.R., Zabala M., Alfaro M., Prieto J., Kramer M.G., Smerdou C. (2014). Short-term intra-tumoral IL-12 expressed from an alphaviral vector is sufficient to induce an efficient anti-tumoral response against spontaneous hepatocellular carcinomas. Human Gene Therapy. 25(2): 132-143.
    ABSTRACT CORTESÍA DE PUBMED

  • Aranda A., Bezunartea J., Casales E., Rodriguez-Madoz J.R., Larrea E., Prieto J., Smerdou C. (2014). A quick and efficient method to generate mammalian stable cell lines based on a novel inducible alphavirus DNA/RNA layered system. Cellular and Molecular Life Sciences. May 3 [Epub ahead of print] DOI 10.1007/s00018-014-1631-2
    ABSTRACT CORTESÍA DE PUBMED

  • Melero I., Quetglas J.I., Reboredo M., Dubrot J., Rodriguez-Madoz J.R., Mancheño U., Casales E., Riezu-Boj J., Ruiz-Guillen M., Ochoa M.C., Sanmamed M.F., Thieblemont N., Smerdou C., Hervas-Stubbs S. (2015). Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL-12. Cancer Research. 75(3):497-507.
    ABSTRACT CORTESÍA DE PUBMED

  • Quetglas J.I., Labiano S., Aznar A., Bolaños E., Azpilikueta A., Rodriguez I., Casales E., Rodríguez A.,  Smerdou C., and Melero I. (2015). Virotherapy with a Semliki Forest Virus-based Vector encoding IL-12 synergizes with PD-1/PD-L1 Blockade. Cancer Immunology Research. 3(5):449-54.
    ABSTRACT CORTESÍA DE PUBMED



"Estamos evaluando el uso de anticuerpos monoclonales (MAbs) con propiedades inmunomoduladoras para el tratamiento del cáncer", Dr. Cristian Smerdou, investigador principal.

Más información:

Contacto

Contacto:
Cristina López
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 6021
clopezg@unav.es